Bayer

683 articles with Bayer

• 

  Bayer Acquires AskBio for Up to $4 Billion to Expand Gene Therapy Platform

  10/26/2020

  Bayer is paying $2 billion upfront for AskBio's AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.

• Bayer’s FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

  10/23/2020

  Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that works on the pathway of MR overactivation, a key contributor to disease progression in patients with chronic kidney disease and type 2 diabetes FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease and type 2 diabetes with a primary composite endpoint exclusively cons

• FDA Approves FoundationOne®CDx as Companion Diagnostic for Vitrakvi® (larotrectinib), to Aid in Identifying NTRK Fusion-Positive Patients

  10/23/2020

  Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, including available biomarker driven treatments FoundationOne ® CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions ( NTRK 1, NTRK 2

• Aliqopa™ (copanlisib) in Combination With Rituximab Meets Primary Endpoint in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

  10/14/2020

  Phase III study CHRONOS-3 in patients with relapsed indolent Non-Hodgkin's Lymphoma (iNHL) who have received one or more prior lines of rituximab-containing therapy meets primary endpoint of progression-free survival

• Bayer to Present Results From Phase III FIDELIO-DKD Study with Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes during Late-Breaker Session at the American Society of Nephrology’s Kidney Week 2020

  10/12/2020

  Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Addition

• Bayer Launches Understand Your Density Campaign in Partnership with HealthyWomen to Increase Education Surrounding Dense Breasts and Supplemental Screening Needs

  10/7/2020

  Bayer Launches Understand Your Density Campaign in Partnership with HealthyWomen to Increase Education Surrounding Dense Breasts and Supplemental Screening Needs - Breast density is the ratio of fibrous tissue vs. fat within the breast and has an impact on cancer risk 1 - Women with dense breasts are more likely to get false-negative results from a mammogram 2 - Online quiz aims to arm women with dense breasts with the information needed to as

• Bayer Celebrates 4-H STEM Challenge by Supplying 1,100+ Mars Base Camp Kits to Students Across the Country

  10/6/2020

  Kits Sent to Educators and Families Provide 11,000 Additional Youth Access to the STEM Education Activities

• TargetCancer Foundation Announces First Patients Enrolled in TRACK Study to Research Genomic Testing in People with Rare Cancers, Supported by Bayer

  9/30/2020

  The TRACK Study has opened to enrollment for people in the U.S. diagnosed with rare cancers, including those with cancer of unknown primary (CUP) Open-label, non-randomized, pragmatic study to address access issues for genomic testing with remote enrollment and consent process and provide patients with information on molecular biomarkers to inform treatment recommendations With support from Bayer and in partnership with Foundation Medicine and

• Bayer’s XtendFlex Soybeans Gain Final Key Regulatory Approval

  9/28/2020

  Bayer announced today that the European Commission has authorized XtendFlex soybean technology for food, feed, import and processing in the European Union. This milestone represents the final key authorization for XtendFlex soybeans. With this approval in hand, Bayer can now look forward to a full launch in the United States and Canada in 2021 and expect

• 

  Clinical Catch-Up: September 21-25

  9/28/2020

  The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

• Bayer Earns Top Honors with 2021 Military Friendly ® Employer Designation

  9/21/2020

  Bayer announced today that it has earned recognition as a 2021 Military Friendly ® Employer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005013/en/ The designation recognizes the company’s proactive efforts to honor, include and encourage veterans and military members through its workplace policies. Such policies at Bayer include expanding hea

• 

  Clinical Catch-Up: September 14-18

  9/21/2020

  It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.

• New Data Support Strong Clinical Profile of Vitrakvi® (larotrectinib) for Adult and Pediatric Patients with TRK Fusion Cancer, Including Lung and Thyroid Tumors

  9/17/2020

  78% overall response rate (ORR) and median progression-free survival (PFS) of 36.8 months demonstrate durable response in expanded data set of 175 adults and children

• 

  A Look at ESMO as Companies Share Oncology Updates

  9/17/2020

  The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.

• Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™

  9/15/2020

  Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. ERSO’s mechanism of action is a therapeutic approach being investigated in women with metastatic ER-positive bre

• Bayer: Supervisory Board Extends CEO Werner Baumann’s Contract Until the End of April 2024

  9/10/2020

  The Supervisory Board of Bayer AG has unanimously decided to extend the contract of Werner Baumann, Chairman of the Board of Management, until April 30, 2024.

• Bayer Completes Acquisition of the UK-based Biotech Company KaNDy Therapeutics Ltd.

  9/9/2020

  Bayer, a global leader in women’s healthcare, announced that, further to its press release on August 11, 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.

• Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases

  9/9/2020

  Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster

•  Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020

  9/8/2020

  Long-term efficacy and safety results of an integrated data set for Vitrakvi® (larotrectinib), as well as sub-analyses, to be presented in poster sessions

• Bayer Phase IV Study Met its Primary Endpoint in PAH Patients Who Had Transitioned to Adempas® (riociguat) After Insufficient Response to PDE5 Inhibitors

  9/7/2020

  Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH)